Skip to content
Screener

Neuropace, Inc. NPCE Q3 2026 earnings

Reported November 12, 2026 · After market close

Revenue$23.1MMiss by $4.0M
EPS-$0.10Beat by $0.01
Revenue estimate$27.1M
EPS estimate-$0.11
“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates. The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated. We are addressing these factors, and fourth-quarter scheduled cases have begun to recover. Ongoing demand for RNS therapy, compelling clinical outcomes and the substantial opportunity within our current indication all remain and reinforce our confidence in the business performing in line with historical growth rates. Our focus is on continuing to translate that opportunity into consistent growth through deeper customer engagement and stronger commercial execution.”
Joel Becker

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$23.1M-15.5%
Gross profit$19.5M-8.0%
Operating income-$2.1M+20.0%
Net income-$3.3M+5.7%
EPS (diluted)-$0.10+9.1%

Balance sheet

See full
Cash & equivalents$10.2M-50.7%
Total debt$69.5M-2.3%
Total equity$11.5M-37.9%
Total assets$94.8M-11.6%

Cash flow

See full
Operating cash flow-$2.8M-42.1%
CapEx$16.0K-46.7%
Free cash flow-$2.8M-40.8%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$450.33M+0.5%
Enterprise value$509.64M+2.3%
P/S4.8×-0.2×

Profitability

See full
Gross margin81.4%+3.4pp
Operating margin-15.4%-3.4pp
Net margin-20%-3.9pp
FCF margin-13.6%-2.8pp

Returns & leverage

See full
Return on equity-126.1%-25.6pp
Debt / equity6.1×+2.2×
Current ratio5.3×+0.4×

FAQ

When did Neuropace, Inc. report Q3 2026 earnings?
Neuropace, Inc. (NPCE) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Neuropace, Inc.'s Q3 2026 revenue and EPS?
Neuropace, Inc. reported revenue of $23.1M and eps of $-0.10 for Q3 2026.
Did Neuropace, Inc. beat estimates in Q3 2026?
Revenue missed the consensus estimate of $27.1M by $4.0M. EPS beat the consensus estimate of $-0.11 by $0.01.
How did Neuropace, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 15.5% from $27.4M a year earlier and eps grew 9.1% from $-0.11.
Where can I find Neuropace, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001528287-26-000037) and the 10-Q periodic report (0001528287-26-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.